Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate
Executive Summary
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.
You may also be interested in...
Blow To Ipsen As FerGene Nabs CEO Meek
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.
Ferring And Blackstone Launch Gene Therapy Company
The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.
Ferring Makes Foray Into Gene Therapy With FKD Pact
The Swiss company's CMO Klaus Dugi tells Scrip that getting the rights to a late-stage bladder cancer gene therapy from Finland's FKD highlights the transformation that Ferring is undergoing.
Need a specific report? 1000+ reports available
Buy Reports